MA45981A - Méthode de prévention ou de traitement de la perte audititive. - Google Patents

Méthode de prévention ou de traitement de la perte audititive.

Info

Publication number
MA45981A
MA45981A MA045981A MA45981A MA45981A MA 45981 A MA45981 A MA 45981A MA 045981 A MA045981 A MA 045981A MA 45981 A MA45981 A MA 45981A MA 45981 A MA45981 A MA 45981A
Authority
MA
Morocco
Prior art keywords
prevention
treatment
hearing loss
hearing
loss
Prior art date
Application number
MA045981A
Other languages
English (en)
Inventor
Alexander Bausch
Original Assignee
Support Venture Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Support Venture Gmbh filed Critical Support Venture Gmbh
Publication of MA45981A publication Critical patent/MA45981A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA045981A 2016-08-17 2017-08-15 Méthode de prévention ou de traitement de la perte audititive. MA45981A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16184541 2016-08-17

Publications (1)

Publication Number Publication Date
MA45981A true MA45981A (fr) 2019-06-26

Family

ID=56740115

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045981A MA45981A (fr) 2016-08-17 2017-08-15 Méthode de prévention ou de traitement de la perte audititive.

Country Status (18)

Country Link
US (1) US20190209568A1 (fr)
EP (1) EP3500258A1 (fr)
JP (1) JP2019528273A (fr)
KR (1) KR20190039142A (fr)
CN (1) CN109562105A (fr)
AU (1) AU2017313296A1 (fr)
BR (1) BR112019003006A2 (fr)
CA (1) CA3033887A1 (fr)
CL (1) CL2019000410A1 (fr)
CO (1) CO2019001402A2 (fr)
EA (1) EA201990220A1 (fr)
IL (1) IL264625A (fr)
MA (1) MA45981A (fr)
MX (1) MX2019001819A (fr)
PE (1) PE20190421A1 (fr)
PH (1) PH12019550015A1 (fr)
SG (1) SG11201900776TA (fr)
WO (1) WO2018033543A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092888A1 (ru) * 2018-07-13 2021-04-19 Кинарус Аг КОМБИНАЦИИ АГОНИСТОВ PPAR И ИНГИБИТОРОВ КИНАЗЫ p38 ДЛЯ ПРЕДОТВРАЩЕНИЯ ИЛИ ЛЕЧЕНИЯ ФИБРОЗИРУЮЩИХ ЗАБОЛЕВАНИЙ

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
US20020151491A1 (en) * 2000-11-28 2002-10-17 Jian-Dong Li Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of MUC5AC
MXPA03007166A (es) 2001-02-12 2003-11-18 Hoffmann La Roche Pirido-pirimidinas 6-sustituidas.
CN100455582C (zh) 2003-11-13 2009-01-28 霍夫曼-拉罗奇有限公司 羟烷基取代的吡啶并-7-嘧啶-7-酮
US8870826B2 (en) 2004-05-24 2014-10-28 Auris Medical Llc Combined otic aspirator and medication dispenser
EP2158182A2 (fr) 2007-06-15 2010-03-03 F. Hoffmann-Roche AG Nouveau procédé de préparation de 3-amino-pentan-1,5-diol
MA41490A (fr) * 2015-02-11 2021-04-07 Support Venture Gmbh Procédé de prévention ou de traitement de la perte auditive
CA3023392C (fr) * 2016-06-08 2024-02-06 Support-Venture Gmbh Combinaison de l'agoniste de ppar et de l'inhibiteur de p38 kinase pour le traitement du cancer

Also Published As

Publication number Publication date
KR20190039142A (ko) 2019-04-10
BR112019003006A2 (pt) 2019-05-14
WO2018033543A1 (fr) 2018-02-22
EP3500258A1 (fr) 2019-06-26
US20190209568A1 (en) 2019-07-11
SG11201900776TA (en) 2019-03-28
AU2017313296A1 (en) 2019-02-14
PH12019550015A1 (en) 2019-07-24
CO2019001402A2 (es) 2019-02-19
JP2019528273A (ja) 2019-10-10
IL264625A (en) 2019-02-28
CL2019000410A1 (es) 2019-06-28
EA201990220A1 (ru) 2019-08-30
CN109562105A (zh) 2019-04-02
PE20190421A1 (es) 2019-03-19
CA3033887A1 (fr) 2018-02-22
MX2019001819A (es) 2019-06-13

Similar Documents

Publication Publication Date Title
EP3384050A4 (fr) Suivi du traitement ou de la progression d'un myélome
EP3519833A4 (fr) Méthodes de pronostic et de traitement
EP3380121A4 (fr) Méthode de traitement de troubles oculaires
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
MA40498A (fr) Méthode de traitement de l'intoxication par organophosphates
BR112017024253A2 (pt) métodos de tratamento de inflamação ou dor neuropática.
EP3522934A4 (fr) Compositions et méthode pour le traitement de la rénopathie
MA47820A (fr) Traitement de la glycogénose de type iii
MX376201B (es) Compuestos inhibidores de metaloenzima.
PT3265087T (pt) Método de tratamento com tradipitant
EP3455188C0 (fr) Procede de traitement de laitier
EP3448365A4 (fr) Méthode de traitement de la constipation
MA41490A (fr) Procédé de prévention ou de traitement de la perte auditive
EP3294761A4 (fr) Compositions et méthodes de traitement et de prévention de l'infection pare. coli
EP3375440A4 (fr) Méthode de traitement de la mucosite
PT3233071T (pt) Método de tratamento ou prevenção de doenças mediadas por ras
EP3445450A4 (fr) Méthode de traitement ou de prévention d'états pathologiques hépatiques
PT3408417T (pt) Método de tratamento térmico
PT3413897T (pt) Métodos de tratamento e profilaxia do vih e sida
EP3440107A4 (fr) Méthode de traitement de l'athérosclérose
EP3634422A4 (fr) Méthodes de traitement de la leucodystrophie
MA41462A (fr) Méthode de traitement de maladies
EP3579837C0 (fr) Axitinib, nintedanib ou lenvatinib pour le traitement de la rosacée et de la dermatite atopique
LT3209319T (lt) Grybelinių infekcijų gydymo būdas
EP3393474A4 (fr) Méthode de traitement de l'ossification hétérotopique